Dupont RL, Rice DP, Miller LS, et al.: Economic costs of anxiety disorders. Anxiety 1996, 2:167–172.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Publishing; 2000.
Stein DJ: Clinical Manual of Anxiety Disorders. Washington, DC: American Psychiatric Publishing; 2004.
Hollander E, Simeon D: Anxiety disorders. In Textbook of Psychiatry, edn 4. Edited by Hales RE, Yudofsky SC, Talbott JA. Washington, DC: American Psychiatric Press; 2003:543–630.
Mattick RP, Andrews G, Hadzi-Pavolic D, et al.: Treatment of panic and agoraphobia: an integrative review. J Nerv Ment Dis 1990, 178:567–576.
Zitrin CM, Klein DF, Woerner MG, et al.: Treatment of phobias I: comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1980, 40:125–138. Although from 1980, this is a landmark study that helped open the current debate.
Gorman J, Shear K, March J, et al.: Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry 1998, 155(suppl):1–28.
Noyes RJ, Burrows GD, Reich JH, et al.: Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996, 57:349–355. This is an interesting example of how study findings are incorporated into clinical practice.
Foa EB, Franklin ME, Moser J: Context in clinic: how well do cognitive-behavioral therapies and medications work in combination?
Biol Psychiatry 2002, 52:987–997. This is a comprehensive and articulate review.
Barlow DH, Gorman JM, Shear MK, et al.: Cognitive-behavioral therapy, imipramine or their combination for panic disorder. JAMA 2000, 283:2529–2536.
Westra HA, Stewart SH: Cognitive-behavioral therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety. Clin Psychol Rev 1998, 18:307–340.
Otto MW, Pollack MH, Sabatino SA: Maintenance and remission following cognitive-behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment. Behav Ther 1996, 27:473–482.
Rosenbaum JF, Pollock RA, Otto MA, et al.: Integrated treatment of panic disorder. Bull Menninger Clin 1995, 59(suppl):A4-A26.
Rickles K, Rynn M: Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002, 63(suppl):9–16.
Ballenger JC, Davidson JRT, Lecrubier Y, et al.: Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 2001, 62(suppl):53–58.
Power KG, Simpson MB, Swanson V, et al.: A controlled comparison of cognitive-behavioral therapy, diazepam, and placebo in the management of generalized anxiety disorder. J Anxiety Disord 1990, 4:267–292.
Bond AJ, Wingrove J, Curran HJ, et al.: Treatment of generalized anxiety disorder with a short course of psychological therapy, combined with buspirone or placebo. J Affect Disord 2002, 72:267–271.
Leckman JF, Grice DE, Boardman J, et al.: Symptoms of generalized anxiety disorder. Am J Psychiatry 1997, 154:911–917.
Sasson Y, Zohar J, Chopra M, et al.: Epidemiology of obsessive compulsive disorder: a world view. J Clin Psychiatry 1997, 58(suppl):7–10.
March JS, Frances A, Carpenter D, et al.: The expert consensus series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997, 58(suppl):5–28.
Albert U, Aguglia E, Maina G, et al.: Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002, 63:1004–1009.
McDougle CJ, Goodman WK, Leckman JF, et al.: A doubleblind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000, 57:794–801.
Cottraux J, Mollard E, Bouvard M, et al.: A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacology 1990, 5:17–30.
Hohagen F, Winkelman G, Rasche-Rauchle H, et al.: Combination of behavior therapy with fluvoxamine in comparison with behavior therapy and placebo. Br J Psychiatry 1998, 173(suppl):71–78.
van Balkom AJ, de Haan E, van Oppen P, et al.: Cognitive and behavioral therapies alone and in combination with fluvoxamine in the treatment of obsessive-compulsive disorder. J Nerv Ment Dis 1998, 186:492–499.
Van Ameringen MA, Lane RM, Walker JR, et al.: Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001, 158:275–281.
Lipsitz JD, Markowitz JC, Cherry S, et al.: Open trial of interpersonal psychotherapy for the treatment of social phobia. Am J Psychiatry 1999, 156:1814–1816.
Gabbard GO: Psychodynamics of panic disorder and social phobia. Bull Menninger Clin 1992, 56(suppl):A3-A13.
Heimberg RG, Liebowitz MR, Hope DA, et al.: Cognitivebehavioral group treatment of social phobia: 12-week outcome. Arch Gen Psychiatry 1998, 55:1133–1141.
Blomhoff S, Haug TT, Hellstrom K, et al.: Randomised controlled general practice trial of sertraline, exposure therapy, and combined treatment in generalized social phobia. Br J Psychiatry 2001, 179:23–30.
Kessler RC, Sonnega A, Bromet E, et al.: Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 1995, 52:1048–1060.
Johnson DR, Rosenheck R, Fontana A, et al.: Outcome of intensive inpatient treatment for combat-related posttraumatic stress disorder. Am J Psychiatry 1996, 153:771–777.
Schnurr PP, Friedman MJ, Foy D: Randomized trial of traumafocused group therapy for posttraumatic stress disorder. Arch Gen Psychiatry 2003, 60:481–489.
Marshall RD, Carcamo JH, Blanco C, et al.: Trauma-focused psychotherapy after a partial response to medication in PTSD: pilot observations. Am J Psychother 2003, 57:374–383.
Otto MW, Hinton D, Korbly NB, et al.: Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther 2003, 41:1271–1276.